Hawkins Amy, Tulloh Robert
Department of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK.
Vasc Health Risk Manag. 2009;5(2):509-24. doi: 10.2147/vhrm.s4171. Epub 2009 Jun 7.
Pulmonary hypertension was once thought to be a rare condition and only managed in specialized centers. Now however, with the advent of echocardiography, it is found in many clinical scenarios, in the neonate with chronic lung disease, in the acute setting in the intensive care unit, in connective tissue disease and in cardiology pre- and postoperatively. We have a better understanding of the pathological process and have a range of medication which is starting to be able to palliate this previously fatal condition. This review describes the areas that are known in this condition and those that are less familiar. The basic physiology behind pulmonary hypertension and pulmonary vascular disease is explained. The histopathologic process and the various diagnostic tools are described and are followed by the current and future therapy at our disposal.
肺动脉高压曾被认为是一种罕见病症,仅在专科中心进行治疗。然而现在,随着超声心动图技术的出现,在许多临床情况下都能发现它,如患有慢性肺病的新生儿、重症监护病房的急性病例、结缔组织病患者以及心脏病手术前后的患者。我们对其病理过程有了更深入的了解,并且有一系列药物开始能够缓解这种以前的致命病症。这篇综述描述了该病症中已知的领域和那些不太为人熟悉的领域。解释了肺动脉高压和肺血管疾病背后的基本生理学原理。描述了组织病理学过程和各种诊断工具,随后介绍了我们目前可用的以及未来的治疗方法。